Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

Courtney D. DiNardo; Eytan M. Stein; Arnaud Pigneux; Jessica K. Altman; Robert Collins; Harry P. Erba; Justin M. Watts; Geoffrey L. Uy; Thomas Winkler; Hongfang Wang; Sung Choe; Hua Liu; Bin Wu; Stephanie M. Kapsalis; Gail J. Roboz; Stéphane de Botton

doi:10.1038/s41375-021-01229-x

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

Courtney D. DiNardo, Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, Geoffrey L. Uy, Thomas Winkler, Hongfang Wang, Sung Choe, Hua Liu, Bin Wu, Stephanie M. Kapsalis, Gail J. Roboz, Stéphane de Botton

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Original language	English
Pages (from-to)	3278-3281
Number of pages	4
Journal	Leukemia
Volume	35
Issue number	11
DOIs	https://doi.org/10.1038/s41375-021-01229-x
State	Published - Nov 2021

Access to Document

10.1038/s41375-021-01229-x

Cite this

DiNardo, C. D., Stein, E. M., Pigneux, A., Altman, J. K., Collins, R., Erba, H. P., Watts, J. M., Uy, G. L., Winkler, T., Wang, H., Choe, S., Liu, H., Wu, B., Kapsalis, S. M., Roboz, G. J., & de Botton, S. (2021). Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia, 35(11), 3278-3281. https://doi.org/10.1038/s41375-021-01229-x

@article{34e85b8474824dfdbb79d6b8f45c8946,

title = "Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant",

author = "DiNardo, {Courtney D.} and Stein, {Eytan M.} and Arnaud Pigneux and Altman, {Jessica K.} and Robert Collins and Erba, {Harry P.} and Watts, {Justin M.} and Uy, {Geoffrey L.} and Thomas Winkler and Hongfang Wang and Sung Choe and Hua Liu and Bin Wu and Kapsalis, {Stephanie M.} and Roboz, {Gail J.} and {de Botton}, St{\'e}phane",

note = "Funding Information: Conflict of interest CDD acted as a consultant/advisor for Agios and Celgene; received honoraria from AbbVie, Agios, Bayer, Celgene, Karyopharm, and MedImmune; and received research funding from AbbVie, Agios, Celgene, and Daiichi Sankyo. EMS holds stock/ ownership interests in Auron; acted as a consultant/advisor for Abb-Vie, Agios, Astellas, Bayer, BioLineRx, Celgene, Daiichi Sankyo, Genentech, Novartis, Pfizer, PTC, and Syros; received research funding from Agios, Amgen, Bayer, Celgene, and Syros; and received travel expenses from AbbVie, Astellas, Celgene, Daiichi Sankyo, Novartis, and Syros. AP acted as a consultant/advisor for AbbVie, Amgen, Astellas, Daiichi Sankyo, Jazz, Pfizer, and Roche; received honoraria from Novartis; and received research travel expenses from Sanofi. JKA acted as a consultant/advisor for AbbVie, Agios, Astellas, Cancer Expert Now, Daiichi Sankyo, GlycoMimetics, Novartis, and Theradex; was on a speakers bureau for France Foundation, PeerView, and prIME Oncology; and received research funding to institution from Agios, Astellas, Boehringer Ingelheim, Celgene, FujiFilm, and Genentech. RC received research funding from Aeglea BioTher-apeutics, Agios, Astellas, MedImmune, and Oregon Health & Science University; HPE acted as a consultant/advisor for Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, GlycoMimetics, ImmunoGen, Incyte, Jazz, MacroGenics, Novartis, Pfizer, and Seattle Genetics; was on a speakers bureau for Agios, Celgene, Incyte, Jazz, and Novartis; received research funding from Agios, Amgen, Daiichi Sankyo, Gly-coMimetics, ImmunoGen, Janssen, Juno, Pfizer, Seattle Genetics, and Takeda; and received other fees from Celgene and GlycoMimetics. JMW acted as a consultant/advisor for Bristol Myers Squibb, Celgene, Genentech, Jazz, Rafael, and Takeda; and received research funding from Takeda. GLU acted as a consultant/advisor for Abbvie, Agios, Astellas, Genentech, GSK, and Jazz. TW, HW, SC, HL, BW, and SMK are employees of and hold stock/ownership interests in Agios. GJR acted as a consultant/advisor or Data and Safety Monitoring Committee member for AbbVie, Actinium, Agios, Amphivena, argenx, Astellas, Astex, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Janssen, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, and Trovagene; and received research funding from Cellectis. SdB acted as a consultant/advisor for Agios, Bayer, CarthaGenetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; received honoraria from AbbVie, Agios, Bayer, CarthaGenetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; received research funding from Agios; received travel expenses from Agios, Cartha-Genetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; and was on a speakers bureau for AbbVie.",

year = "2021",

month = nov,

doi = "10.1038/s41375-021-01229-x",

language = "English",

volume = "35",

pages = "3278--3281",

journal = "Leukemia",

issn = "0887-6924",

number = "11",

}

DiNardo, CD, Stein, EM, Pigneux, A, Altman, JK, Collins, R, Erba, HP, Watts, JM, Uy, GL, Winkler, T, Wang, H, Choe, S, Liu, H, Wu, B, Kapsalis, SM, Roboz, GJ & de Botton, S 2021, 'Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant', Leukemia, vol. 35, no. 11, pp. 3278-3281. https://doi.org/10.1038/s41375-021-01229-x

TY - JOUR

T1 - Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

AU - DiNardo, Courtney D.

AU - Stein, Eytan M.

AU - Pigneux, Arnaud

AU - Altman, Jessica K.

AU - Collins, Robert

AU - Erba, Harry P.

AU - Watts, Justin M.

AU - Uy, Geoffrey L.

AU - Winkler, Thomas

AU - Wang, Hongfang

AU - Choe, Sung

AU - Liu, Hua

AU - Wu, Bin

AU - Kapsalis, Stephanie M.

AU - Roboz, Gail J.

AU - de Botton, Stéphane

N1 - Funding Information: Conflict of interest CDD acted as a consultant/advisor for Agios and Celgene; received honoraria from AbbVie, Agios, Bayer, Celgene, Karyopharm, and MedImmune; and received research funding from AbbVie, Agios, Celgene, and Daiichi Sankyo. EMS holds stock/ ownership interests in Auron; acted as a consultant/advisor for Abb-Vie, Agios, Astellas, Bayer, BioLineRx, Celgene, Daiichi Sankyo, Genentech, Novartis, Pfizer, PTC, and Syros; received research funding from Agios, Amgen, Bayer, Celgene, and Syros; and received travel expenses from AbbVie, Astellas, Celgene, Daiichi Sankyo, Novartis, and Syros. AP acted as a consultant/advisor for AbbVie, Amgen, Astellas, Daiichi Sankyo, Jazz, Pfizer, and Roche; received honoraria from Novartis; and received research travel expenses from Sanofi. JKA acted as a consultant/advisor for AbbVie, Agios, Astellas, Cancer Expert Now, Daiichi Sankyo, GlycoMimetics, Novartis, and Theradex; was on a speakers bureau for France Foundation, PeerView, and prIME Oncology; and received research funding to institution from Agios, Astellas, Boehringer Ingelheim, Celgene, FujiFilm, and Genentech. RC received research funding from Aeglea BioTher-apeutics, Agios, Astellas, MedImmune, and Oregon Health & Science University; HPE acted as a consultant/advisor for Agios, Amgen, Astellas, Celgene, Daiichi Sankyo, GlycoMimetics, ImmunoGen, Incyte, Jazz, MacroGenics, Novartis, Pfizer, and Seattle Genetics; was on a speakers bureau for Agios, Celgene, Incyte, Jazz, and Novartis; received research funding from Agios, Amgen, Daiichi Sankyo, Gly-coMimetics, ImmunoGen, Janssen, Juno, Pfizer, Seattle Genetics, and Takeda; and received other fees from Celgene and GlycoMimetics. JMW acted as a consultant/advisor for Bristol Myers Squibb, Celgene, Genentech, Jazz, Rafael, and Takeda; and received research funding from Takeda. GLU acted as a consultant/advisor for Abbvie, Agios, Astellas, Genentech, GSK, and Jazz. TW, HW, SC, HL, BW, and SMK are employees of and hold stock/ownership interests in Agios. GJR acted as a consultant/advisor or Data and Safety Monitoring Committee member for AbbVie, Actinium, Agios, Amphivena, argenx, Astellas, Astex, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Janssen, Jazz, MEI Pharma, Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda, and Trovagene; and received research funding from Cellectis. SdB acted as a consultant/advisor for Agios, Bayer, CarthaGenetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; received honoraria from AbbVie, Agios, Bayer, CarthaGenetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; received research funding from Agios; received travel expenses from Agios, Cartha-Genetics, Celgene, FORMA, Novartis, Pfizer, Pierre Fabre, Seattle Genetics, and Servier; and was on a speakers bureau for AbbVie.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85103135624&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01229-x

DO - 10.1038/s41375-021-01229-x

M3 - Article

C2 - 33772143

AN - SCOPUS:85103135624

SN - 0887-6924

VL - 35

SP - 3278

EP - 3281

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

Access to Document

Other files and links

Cite this